

4DMedical secures participation in pivotal burn pit research grant

1 March 2024

Highlights

- The Military Exposures Research Program (MERP), an initiative of the U.S. Department of Veterans Affairs (VA), has awarded a grant to the Nashville Veterans Affairs Medical Center, in partnership with Vanderbilt University Medical Center (VUMC) and the Vanderbilt University Institute of Imaging Sciences (VUISS).
- This study will utilise 4DMedical's XV Technology® to positively impact Veterans by advancing the understanding of factors which cause deployment related respiratory disease (DRRD) and improving the ability of clinicians to diagnose DRRD non-invasively.
- XV Technology® will be used to characterise Veterans with biopsy-confirmed DRRD in order to understand disease progression and create new surrogate endpoints for future clinical trials

Melbourne, Australia, 1 March 2024: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, "4DMedical", or the "Company") today announces the signing of an agreement with Vanderbilt University Medical Center (VUMC) as part of a grant awarded by the U.S. Department of Veterans Affairs (VA).

The Military Exposures Research Program (MERP), an Office of Research and Development (ORD) initiative of the VA, seeks to advance military exposure assessments and to understand the effects of military exposures on Veterans' health outcomes to inform care and policy. MERP grant funding by the VA has enabled deployment of XV LVAS® at the Vanderbilt University Institute for Imaging Sciences (VUISS) in Nashville, Tennessee, a hub for Veterans' health research.

4DMedical's participation in this pivotal burn pit research grant follows a previous successful collaboration with VUMC. On 31 August 2022, the Company announced a major milestone in a clinical trial conducted at VUMC in partnership with Nashville Veterans Affairs Medical Center. This study was designed to test the capability of XV Technology® to determine the presence of respiratory disease in Veterans exposed to airborne hazards while on deployment. The study enrolled a group of Veterans who had surgical lung biopsy-confirmed deployment-related constrictive bronchiolitis (CB) and a control group. Results from the study demonstrated that XV Technology® confirmed the diagnosis of CB, setting it apart from conventional diagnostic methods such as CT and pulmonary function testing (PFT), and as a dramatically safer and less expensive alternative to surgical biopsy.

Bradley W. Richmond M.D., Ph.D., Assistant Professor in the Department of Allergy, Pulmonary, and Critical Care, at Vanderbilt University Medical Center and a staff physician at the Nashville VA, said, "Vanderbilt University Medical Center was one of the earliest collaborative partners of 4DMedical and is utilising 4DMedical's X-ray Velocimetry software (XV Technology®) to develop radiographic biomarkers for diagnosis and prognostication in multiple diseases including deployment-related respiratory disease (DRRD), candidate selection for bronchoscopic lung volume reduction (BLVR) in COPD, and in early diagnosis of chronic lung allograft dysfunction after lung transplantation. While CT scans offer anatomic information, 4DMedical's XV Technology® lets us evaluate actual lung function in real-time. 4DMedical's recent acquisition of Imbio is also exciting as Imbio's suite of CT-based analysis tools complements XV Technology® and has broad

Melbourne

Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles

21255 Burbank Boulevard
Suite 120
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com



application across multiple pulmonary disease domains." The study is funded by the U.S. Department of Veterans Affairs.

4DMedical MD/CEO and Founder Andreas Fouras said:

4DMedical's inclusion in this pivotal study cements our position as a leading technology for Veterans exposed to burn pits. 4DMedical's XV Technology® will assist Veterans, clinicians and researchers at the VA to detect lung disease associated with toxic exposure sensitively and non-invasively. This project, combined with our recent news regarding the use of Imbio's LTA to detect pulmonary fibrosis in Veterans, highlights the growing profile and momentum 4D has at the VA, and I look forward to sharing further updates in the coming months.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Chief Financial Officer

Simon Glover

sglover@4dmedical.com

Administration

Company Secretary

Naomi Lawrie

companysecretary@4dmedical.com

Media Enquiries

The Capital Network (TCN)

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio's regulatory-cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity and more personalised care for patients.

To learn more, please visit www.4dmedical.com and www.imbio.com.